Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Corporate Update (July 2025)
12 slides from Neurizon Therapeutics's corporate update, Jul 2, 2025
Slide 1: Presentation Materials – Shareholder Webinar on Licensing Agreement
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Presentation Materials – Shareholder Webinar on Licensing Agreement 02 July 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to ad
Slide 2: Shaping the future of neurodegenerative diseases
For personal use only Shaping the future of neurodegenerative diseases Elanco Licensing Agreement Webinar 02 July 2025 ASX: NUZ
Slide 3: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it Future Matters (This presentation has been prepared by Neurizon® Therapeutics Limited (ASX: NUZ) (the “Company”). It does not purport to contain all the information that a prospective in
Slide 4: Our vision is to lead the development of neurodegenerative treatments
For personal use only Our vision is to lead the development of neurodegenerative treatments towards a promising new horizon for patients 3
Slide 5: Our mission and strategic focus
Our mission is to advance innovative, disease-modifying therapies that address the underlying pathology and drivers of neurodegenerative conditions For personal use only Our success is underpinned by a clear strategic focus on: Elanco Licensing Agreement Webinar, July 2025 4
Slide 6: NUZ-001: A Platform Molecule for Proteinopathy-Driven Diseases
NUZ-001: A Platform Molecule for Proteinopathy-Driven Diseases Impaired proteostasis contributes to intracellular inclusion bodies of misfolded proteins is a hallmark of For personal use only neurodegenerative diseases TDP-43 Amyloid beta Tau alpha Synuclein mHTT ALS/AD/PD/FTD/CTE AD/PD AD/PD/FTD/CT
Slide 7: Our Strategic Progress
Our Strategic Progress For personal use only Our initial focus is on advancing clinical work on ALS, following acceptance into the HEALEY ALS Platform Trial Regulatory and Commercialisation Requirements for Realisation • Access to animal safety data and manufacturing data critical to • Access to man
Slide 8: Global License with Elanco
Global License with Elanco For personal use only Exclusive global rights to Elanco’s data package and intellectual property LICENSE AGREEMENT SUPPLY AGREEMENT License Agreement: A foundational step in formalising Neurizon’s Supply Agreement: Agreed and planned next step in further expanding relation
Slide 9: Accelerated & Streamlined Path to NDA and Launch
Accelerated & Streamlined Path to NDA and Launch Elanco Licensing Agreement For personal use only Module 1 Module 2 Module 3 Module 4 Module 5 Administrative Summary Quality Non-Clinical Clinical Documents 01 Comprehensive non-clinical safety Fast Track Designation License Agreement package allows f
Slide 10: FDA Review
FDA Review Progressing Toward Clinical Hold Resolution: PK Studies in Progress / For personal use only Complete Response on Track Regulatory Support PK Studies • The FDA continues to review our strategy to address the clinical hold • Two pharmacokinetic studies placed at leading CRO • Neurizon rema
Slide 11: Investment credentials for NUZ-001
Investment credentials for NUZ-001 De-risked clinical program for a rare neurodegenerative disease positioned for near-term For personal use only regulatory approval and launch Well-characterized Drug Strategic Agreements ✓ ✓ • Oral bioavailable • Access to extensive data and IP • Crosses the Blood
Slide 12: Thank You
For personal use only Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com